|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia显示文摘Objective: The purposes of this study were to assess the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia (AL) and analyze the factors affecting the prognosis of these patients. Methods: The clinical and follow-up data of 93 AL patients (median age, 30 years) undergoing allogeneic HSCT in Xiangya Hospital over the past 12 years were collected, and the potential factors affecting the efficacy and prognosis of allogeneic HSCT patients were determined. Results: Hematopoietic reconstitution was achieved in 90 patients. At the last follow-up, the incidences of severe acute graft versus host disease (aGvHD) and extensive chronic GvHD (cGvHD) were 14.0% and 20.0%, the 3-year cumulative incidence of transplantation related mortality (TRM) and relapse rate were 16.8%±6.1% and 21.3%±6.7%, and the estimated 3-year overall survival (OS) and disease-free survival (DFS) of the patients were 64.6%±5.4% and 56.5%±5.5%, respectively. Univariate analysis indicated that age older than 40 years, HLA mismatch, and severe lung infection within the first 100 days after transplantation were risk factors for severe aGvHD, age older than 40 years, HLA mismatch, severe lung infection within the first 100 days after transplantation, and severe aGvHD were risk factors for TRM, high-risk AL and lack of cGvHD were risk factors for relapse (all P<0.05). Survival estimation showed that HLA mismatch, severe lung infection occurring within the first 100 days post-transplantation, high-risk AL severe aGvHD and lack of cGvHD were risk factors associated with poor prognosis (all P<0.05). Further multivariate analyses revealed that severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD were independent risk factors for unfavorable outcomes (all P<0.05). Conclusions: Allogeneic HSCT can improve the DFS of AL patients, and severe lung infection within the first 100 days post-transplantation, severe aGvHD and lack of cGvHD are independent risk factors affecting the prognosis. | Yan Chen Yajing Xu Gan Fu Yi Liu Jie Peng Bin Fu Xiaoyu Yuan Hongya Xin Yan Zhu Qun He Dengshu Wu Yigang Shu Xiaolin Li Xielan Zhao Fangping Chen | 2013 | Chinese Journal of Cancer Research2013，25，4： | 3 |
| 2 | Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating HSP70 in SHSY-5Y cells显示文摘Background:Mesencephalic astrocyte-derived neurotrophic factor(MANF)is a new candidate growth factor for dopaminergic neurons against endoplasmic reticulum stress(ER stress).HSP70 family,a chaperon like heat shock protein family,was proved to be involved in the MANF induced survival pathway in 6-OHDA treated SHSY-5Y cells.However,the ER stress relative transcriptome,in MANF signaling cascades is still investigated.The involvement of HSP70,a 70kd member of HSP70 family,need further to be verified.Methods:The cell apoptosis was assayed by MTT,TUNEL staining and western blot of cleaved Caspase-3.The differentially expressed genes in SHSY-5Y cells under different conditions(control,6-OHDA,6-OHDA+MANF)were investigated by RNA-seq.Expression of HSP70 was further confirmed by real-time PCR.RNAi knockdown for HSP70 was performed to investigate the role of HSP70 in the MANF signaling pathway.Results:MANF inhibits 6-OHDA-induced apoptosis in SHSY-5Y cells.Six ER stress relative genes(HSP70,GRP78,xbp-1,ATF-4,ATF-6,MAPK)were found enriched in 6-OHDA+MANF treatment group.HSP70 was the most significantly up-regulated gene under 6-OHDA+MANF treatment in SHSY-5Y cells.RNAi knockdown for HSP70 inhibits the protective effects of MANF against 6-OHDA toxicity in SHSY-5Y cells.Conclusion:MANF exerts a protective role against 6-OHDA induced apoptosis in SHSY-5Y cells via up-regulating some ER stress genes,including HSP70 family members.The HSP70 expression level plays a key role in MANFmediated survival pathway. | Hui Sun Ming Jiang Xing Fu Qiong Cai Jingxing Zhang Yanxin Yin Jia Guo Lihua Yu Yun Jiang Yigang Liu Liang Feng Zhiyu Nie Jianmin Fang Lingjing Jin | 2017 | Translational Neurodegeneration2017，6，1： | 2 |
| 3 | Biodiversity analysis of microbial community in the chem-bioflocculation treatment process显示文摘 | Siqing Xia Feng Wang Yigang Fu | 2005 | Biotechnology and Bioengineering2005，89，6： | 1 |
| 4 | DGGE analysis of 16S rDNA of ammonia-oxidizing bacteria in chemical–biological flocculation and chemical coagulation systems显示文摘 | Siqing Xia Yan Shi Yigang Fu Xingmao Ma | 2005 | Applied Microbiology and Biotechnology2005，，1： | 1 |
| 5 | Biodiversity analysis of microbial community in the chem-bioflocculation treatment process显示文摘 | Siqing Xia Feng Wang Yigang Fu | 2005 | Biotechnology and Bioengineering2005，89，6： | 1 |
| 6 | DGGE analysis of 16S rDNA of ammonia-oxidizing bacteria in chemical-biological and chemical coagulation systems显示文摘 | Siqing Xia Yan Shi Yigang Fu | 2005 | Environmental Biotechnology2005，69，1： | 1 |
| 7 | 中国学术期刊文摘(科技快报)显示文摘 | Fu Chengpeng Li Yigang Liu Weiwei | | 中国学术期刊文摘0，，： | 1 |
| 8 | Scientific objectives and payload configuration of the Chang’E-7 mission显示文摘As the cornerstone mission of the fourth phase of the Chinese Lunar Exploration Program,Chang’E-7(CE-7)was officially approved,and implementation started in 2022,including a main probe and a communication relay satellite.The main probe,consisting of an orbiter,a lander,a rover and a mini-flying probe,is scheduled to be launched in 2026.The lander will land on Shackleton crater’s illuminated rim near the lunar south pole,along with the rover and mini-flying probe.The relay satellite(named Queqiao-2)will be launched in February 2024 as an independent mission to support relay communication during scientific exploration undertaken by Chang’E-4,the upcoming Chang’E-6 in 2024 and subsequent lunar missions.The CE-7 mission is mainly aimed at scientific and resource exploration of the lunar south pole.We present CE-7’s scientific objectives,the scientific payloads configuration and the main functions for each scientific payload with its key technical specifications. | Chi Wang Yingzhuo Jia Changbin Xue Yangting Lin Jianzhong Liu Xiaohui Fu Lin Xu Yun Huang Yufen Zhao Yigang Xu Rui Gao Yong Wei Yuhua Tang Dengyun Yu Yongliao Zou | 2024 | National Science Review2024，11，2： | 0 |
| 9 | Mouse model for pangolin-origin coronavirus GX/P2V/2017 infection and cross-protection from COVID-19 ZF2001 subunit vaccine显示文摘Many severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)–related coronaviruses have been discovered,constituting potential threats to human health.However,it remains unclear whether the currently available vaccines are effective against these coronaviruses.Here,we constructed a wild-type mouse model to evaluate pathogenicity of the SARS-CoV-2-related pangolin coronavirus GX/P2V/2017 and neutralization efficacy of the approved tandemrepeat SARS-CoV-2 spike receptor-binding domain(RBD)vaccine ZF2001.We found that ZF2001-induced cross-reactive and cross-neutralizing antibodies against GX/P2V/2017,and the vaccination alleviated the pathological lung damage caused by GX/P2V/2017 in mice.These results indicate that RBD may work as a promising candidate for pan-coronavirus vaccine development. | Xiao Qu Yunfei Jia Na Jia Huahao Fan Anqi Zheng Luoyuan Xia Zhenfei Wang Di Tian Sheng Niu Yu Hu Wenxia Tian Zhihai Chen Yigang Tong Yuwei Gao Wuchun Cao Qihui Wang George Fu Gao | 2023 | hLife2023，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员